Please assess the completion status of the following clinical trial:

Trial Title: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ≥65 years of age and men ≥40 years of age with established CVD (see criterion 'a' below) or ≥50 years of age with diabetes and one additional CV risk factor (see criterion 'b' below)~   1. Those with established CVD should have ≥1 of the following clinical history~      * Documented coronary artery disease (CAD)~        * Prior MI~       * Multivessel CAD (≥50% stenosis in ≥2 major epicardial coronary arteries)~       * Hospitalization for high-risk non-ST-segment elevation acute coronary syndrome~     * Documented cerebrovascular or carotid disease (≥1 of the following)~        * Prior ischemic stroke~       * Carotid artery disease with ≥50% stenosis~       * History of carotid revascularization~     * Documented peripheral artery disease (≥1 of the following)~        * Ankle-brachial index (ABI) \<0.9 with symptoms of intermittent claudication~       * History of aorto-iliac or peripheral arterial intervention~  2. Those with a history of diabetes (either type 1 or type 2 diabetes mellitus) but no CVD should also have ≥1 of the following:~      * Cigarette smoker or stopped smoking within 3 months before the baseline visit~     * Documented hypertension OR on antihypertensive agents~     * HDL-C ≤1.0 mmol/L for men or ≤1.3 mmol/L for women~     * High sensitivity C-reactive protein \>3.0 mg/L~     * eGFR 30 to 60 mL/min/1.73m2~     * Documented micro- or macro-albuminuria~     * Retinopathy~        * Non-proliferative retinopathy~       * Preproliferative or proliferative retinopathy~       * Maculopathy~       * Advanced diabetic retinopathy~       * History of photocoagulation~     * ABI \<0.9 without symptoms of intermittent claudication~2. Elevated triglycerides (≥1.5 mmol/L but \<5.6 mmol/L)~3. On stable statin therapy for ≥4 weeks at the baseline visit~4. Willing to provide written informed consent and be compliant with the study requirements~5. Willing and able to follow the diet recommended by the study doctor~Exclusion Criteria:~1. Participation in another clinical trial with an investigational agent ≤90 days prior to screening~2. Women who are of childbearing potential~3. Any condition or therapy which the study doctor thinks might pose a risk to the participant~4. Severe (New York Heart Association class IV) heart failure~5. Any life-threatening disease expected to result in death within the next 2 years~6. Diagnosis or laboratory evidence of active severe liver disease~7. HbA1c \>10.0% at the baseline visit~8. SBP ≥200 mmHg or DBP ≥100 mmHg (despite being on antihypertensive therapy)~9. Planned coronary intervention or any non-cardiac major surgical procedure~10. Known familial lipoprotein lipase deficiency, apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia~11. Statin intolerant or hypersensitivity to statin therapy~12. Require peritoneal dialysis or hemodialysis~13. eGFR \<30 mL/min/1.73m2~14. History of atrial fibrillation~15. History of major bleeding event(s)~16. Documented history of pancreatitis~17. Malabsorption syndrome and/or chronic diarrhea~18. Known acquired immunodeficiency syndrome~19. Unexplained elevated creatine kinase concentration \>5 × the upper limits of normal or elevation due to known muscle disease~20. Use of niacin, fibrates, omega-3 fatty acids, dietary supplements containing omega-3 fatty acids, bile acid sequestrants or PCSK9 inhibitors~21. Known hypersensitivity to fish and/or shellfish, or ingredients of IPE~22. Inability to swallow IPE capsules whole~23. Drug or alcohol abuse within the past 6 months, and inability/unwillingness to abstain from drug abuse and excessive alcohol consumption during the study~24. Mental/psychological concerns or any other reason to expect difficulty in complying with the study requirements or understanding the goal and potential risks of being a part of the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Icosapent Ethyl + Standard of Care (Type: EXPERIMENTAL): Icosapent Ethyl 1000 MG Oral Capsule \[Vascepa\] 2 x 1g capsules BID (4g total) as per REDUCE-IT
- Standard of Care (Type: NO_INTERVENTION): Standard of care therapy (including statin therapy as per inclusion criteria)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete